Androgen therapy for anemia in elderly uremic patients.
Androgens were the mainstay of treatment of renal anemia prior to the introduction of recombinant human erythropoietin. With the introduction of this recombinant hormone, the protocols of treatment of anemia were completely modified, and the use of androgens was relegated to the background. However, several authors have continued showing interest in the use of androgenic steroids for the treatment of anemia. This review examines several aspects of aging on androgenic hormones and hematopoiesis, the effects of androgen administration on hematological parameters, the side effects of these compounds and the future of this treatment for anemia in renal patients.
Navarro
J F
JF
Nephrology Service, Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Tenerife, Spain. jnavarro@hcan.rcanaria.es
Mora
C
C
D000368:Aged; D000375:Aging / Q000502:physiology; D000728:Androgens / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D011994:Recombinant Proteins
D000728:Androgens; D011994:Recombinant Proteins; D004921:Erythropoietin